Pages that link to "Q44401684"

The following pages link to The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy (Q44401684):

Displaying 29 items.

• Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses (Q21144267) (← links)
• Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system (Q25257352) (← links)
• Comprehensive analysis of HE4 expression in normal and malignant human tissues (Q30440200) (← links)
• A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect (Q34008026) (← links)
• Towards gene therapy of postoperative adhesions: fiber and transcriptional modifications enhance adenovirus targeting towards human adhesion cells (Q34231763) (← links)
• Toward gene therapy of endometriosis: transductional and transcriptional targeting of adenoviral vectors to endometriosis cells (Q34314771) (← links)
• Oncolytic virotherapy for ovarian cancer (Q35597082) (← links)
• Targeting lung cancer using an infectivity enhanced CXCR4-CRAd (Q35754085) (← links)
• Gene therapy of benign gynecological diseases (Q35770271) (← links)
• Tissue-specific promoters for cancer gene therapy (Q35779378) (← links)
• Adenoviruses for treatment of cancer (Q36132288) (← links)
• The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway (Q36190618) (← links)
• Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses (Q36387918) (← links)
• Adenoviral vectors--how to use them in cancer gene therapy? (Q36419822) (← links)
• Gene transfer approaches for gynecological diseases (Q36464907) (← links)
• Gene therapy of gynaecological diseases (Q36922247) (← links)
• Conditionally replicative adenoviral vectors for imaging the effect of chemotherapy on pancreatic cancer cells (Q39151214) (← links)
• Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma (Q39386060) (← links)
• Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment (Q39851910) (← links)
• Enhancing Adenoviral-Mediated Gene Transfer and Expression to Endometrial Cells (Q40006009) (← links)
• Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells (Q40297448) (← links)
• The carcinoma-specific epithelial glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context (Q40386087) (← links)
• A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma (Q40582627) (← links)
• Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer. (Q42321812) (← links)
• Development of a therapeutic adenoviral vector for cholangiocarcinoma combining tumor-restricted gene expression and infectivity enhancement (Q43977774) (← links)
• Expression-targeted gene therapy for the treatment of transitional cell carcinoma (Q45875775) (← links)
• Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines (Q47154025) (← links)
• Targeted gene therapy of the HSV-TK/hIL-12 fusion gene controlled by the hSLPI gene promoter of human non-small cell lung cancer in vitro. (Q54112053) (← links)
• Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis (Q81299152) (← links)